Evaluation of ibuprofen loaded solid lipid nanoparticles and its combination regimens for pancreatic cancer chemoprevention

International Journal of Oncology

Volumn 46, Issue 4, 2015, Pages 1827-1834

  Thakkar, Arvind ^a   Chenreddy, Sushma ^a   Wang, Jeffrey ^a   Prabhu, Sunil ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Chemoprevention; Drug delivery system; Ibuprofen; Pancreatic cancer; Solid lipid nanoparticles; Sulforaphane

Indexed keywords

GLYCEROL BEHENATE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLOXAMER; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; STEARIC ACID; SULFORAPHANE; TRIPALMITIN; ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; LIPID; NANOCONJUGATE; STEARIC ACID DERIVATIVE; SULFORAFAN;

ARTICLE; BINDING ASSAY; CELL VIABILITY; CHEMOPROPHYLAXIS; COLONY FORMATION; DNA BINDING; DOWN REGULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MALE; NANOENCAPSULATION; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOPREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IBUPROFEN; ISOTHIOCYANATES; LIPIDS; NANOCONJUGATES; PANCREATIC NEOPLASMS; STEARIC ACIDS;

EID: 84923092487     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2879     Document Type: Article

References (33)

1. SIEGEL R, MA J, ZOU Z and JEMAL A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. GRANDHI BK, THAKKAR A, WANG J and PRABHU S: A novel combinatorial nanotechnology-based Oral chemopreventive regimen demonstrates significant suppression of pancreatic Cancer neoplastic lesions. Cancer Prev Res 6: 1015-1025, 2013.
3. CHAUDHARY A, SUTARIA D, HUANG Y, WANG J and PRABHU S: Chemoprevention of colon Cancer in a rat Carcinogenesis model using a novel nanotechnology-based combined treatment system. Cancer Prev Res 4: 1655-1664, 2011.
4. THAKKAR A, SUTARIA D, GRANDHI BK, WANG J and PRABHU S: The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncol Rep 29: 1671-1677, 2013.
5. SUTARIA D, GRANDHI BK, THAKKAR A, WANG J and PRABHU S: Chemoprevention of pancreatic Cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulfo-raphane drug combination regimen. Int J Oncol 41: 2260-2268, 2012.
6. PALAYOOR ST, BUMP EA, CALDERWOOD SK, BARTOL S and COLEMAN CN: Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res 4: 763-771, 1998.
7. YAO M, ZHOU W, SANGHA S, et al: Effects of nonselective cyclo-oxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 11: 1618-1628, 2005.
8. BONELLI P, TUCCILLO FM, FEDERICO A, et al: Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric Cancer cells exerts antiproliferative activity at very low concentrations. Int J Nanomed 7: 5683-5691, 2012.
9. LANAS A: A review of the gastrointestinal safety data-a gastro-enterologist's perspective. Rheumatology 49 (Suppl 2): Ii3-ii10, 2010.
10. MALLEN SR, ESSEX MN and ZHANG R: Gastrointestinal tolerability of NSAIDs in elderly patients: A pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin 27: 1359-1366, 2011.
11. BRIGGER I, DUBERNET C and COUVREUR P: Nanoparticles in Cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651, 2002.
12. POTTA SG, MINEMI S, NUKALA RK, et al: Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility. J Microencapsul 28: 74-81, 2011.
13. KOKAWA A, KONDO H, GOTODA T, et al: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 91: 333-338, 2001.
14. O'DRISCOLL CM: Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15: 405-415, 2002.
15. MEHNERT W and MÄDER K: Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47: 165-196, 2001.
16. MATUSHESKI N V, JUVIK JA and JEFFERY EH: Heating decreases epithiospecifier protein activity and increases sulforaphane formation in broccoli. Phytochemistry 65: 1273-1281, 2004.
17. FAHEY J W, HARISTOY X, DOLAN PM, et al: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA 99: 7610-7615, 2002.
18. KUROIWA Y, NISHIKAWA A, KITAMURA Y, et al: Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic Carcinogenesis in hamsters. Cancer Lett 241: 275-280, 2006.
19. CHUNG FL, CONAWAY CC, RAO CV and REDDY BS: Chemo-prevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 21: 2287-2291, 2000.
20. KALLIFATIDIS G, RAUSCH V, BAUMANN B, et al: Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced anti-apoptotic signalling. Gut 58: 949-963, 2009.
21. SZE A, ERICKSON D, REN L and LI D: Zeta-potential measurement using the Smoluchowski equation and the slope of the current-time relationship in electroosmotic fow. J Colloid Interface Sci 261: 402-410, 2003.
22. PETERSEN S, STEINIGER F, FISCHER D, FAHR A and BUNJES H: The physical state of lipid nanoparticles infuences their effect on in vitro Cell viability. Eur J Pharm Biopharm 79: 150-161, 2011.
23. SCHÖLER N, HAHN H, MÜLLER RH and LIESENFELD O: Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 231: 167-176, 2002.
24. SCHÖLER N, OLBRICH C, TABATT K, MÜLLER RH, HAHN H and LIESENFELD O: Surfactant, but not the size of solid lipid nanopar-ticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm 221: 57-67, 2001.
25. ARNARSON T and ELWORTHY PH: Effects of structural variations on non-ionic surfactants on micellar properties and solubilization: Surfactants containing very long hydrocarbon chains. J Pharm Pharmacol 33: 141-144, 1981.
26. SANNA V, CARIA G and MARIANI A: Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of Econazole nitrate. Powder Technol 201: 32-36, 2010.
27. PATIL S, SANDBERG A, HECKERT E, SELF W and SEAL S: Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 28: 4600-4607, 2007.
28. BERNFELD M, GÖTTE M, PARK PW, et al: Functions of Cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777, 1999.
29. WIN KY and FENG SS: Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for Oral delivery of Anticancer drugs. Biomaterials 26: 2713-2722, 2005.
30. CHENG H, ZHU JL, ZENG X, JING Y, ZHANG XZ and ZHUO RX: Targeted Gene delivery mediated by folate-polyethylenimine-block-poly(ethylene glycol) with receptor selectivity. Bioconjug Chem 20: 481-487, 2009.
31. AL-WADEI HA, AL-WADEI MH, ULLAH MF and SCHULLER HM: Celecoxib and GABA cooperatively prevent the progression of pancreatic Cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS One 7: E43376, 2012.
32. MUKHERJEE P, BASU GD, TINDER TL, et al: Progression of pancreatic adenocarcinoma is signifcantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182: 216-224, 2009.
33. STREICHER SA, YU H, LU L, KIDD MS and RISCH HA: Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 23: 1254-1263, 2014.